Six-Month Periodic Fasting in Patients With Type 2 Diabetes and Diabetic Nephropathy: A Proof-of-Concept Study
A proof-of-concept trial in 40 adults with type 2 diabetes and early kidney changes.
J Clin Endocrinol Metab, 2022. Sulaj A, et al.
Funding and competing interests (as published with the paper): Disclosures: The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. L-Nutra, as funder of the fasting-mimicking diet used in this study, has no role in the design or conduct of the study nor in the preparation, review, or approval of the manuscript. V.L. is founder and shareholder of L-Nutra; his shares are destined to the Create Cures Foundation and other charitable and research organizations.
- Study type
- Human clinical trial (proof-of-concept, n=40)
- Journal
- J Clin Endocrinol Metab
- Published
- 2022
- Authors
- Sulaj A, et al.
- DOI
- 10.1210/clinem/dgac197
- PubMed ID
- 35661214
Summary
Forty adults with type 2 diabetes and elevated urinary albumin (an early kidney-change marker) were randomly assigned to a monthly Fasting Mimicking Diet (FMD) or to a Mediterranean diet for six months, with three months of follow-up, to see whether periodic fasting affects albuminuria and related pathways.
The authors reported that FMD was well tolerated, with most participants reporting no adverse effects. Overall change in the albumin-to-creatinine ratio did not differ between groups, but in a subgroup with lower baseline albumin levels the FMD group showed a reduction; in exploratory measures, the FMD group also showed reduced insulin resistance and a lower level of a marker linked to cellular senescence, with the insulin-resistance reduction still present at follow-up.
This is a proof-of-concept study in a specific patient group (type 2 diabetes with early kidney changes), not a study of a general wellness population or of Prolon directly, and several of its positive findings were in a subgroup, not the full study group.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
